Male Breast Cancer
Many men diagnosed with breast cancer have problems while taking tamoxifen and about 20% of them stop taking it because of unacceptable side effects.
The FDA has approved Ibrance to treat men diagnosed with advanced-stage hormone-receptor-positive, HER2-negative breast cancer.
Postmenopausal women and men diagnosed with advanced-stage hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation lived about 8 months longer when treated with the combination of the targeted therapy Piqray and the hormonal therapy Faslodex compared to Faslodex alone.
Similar to studies in women, Black men are more likely to have more aggressive breast cancer than white men.
A study suggests that there are differences in the characteristics of cancers linked to a BRCA1 mutation compared to those of cancers linked to a BRCA2 mutation in men.
Men who have been diagnosed with breast cancer have a higher risk of developing a second, new cancer.
Men have worse survival than women when diagnosed with early-stage breast cancer.
A large study has found that men diagnosed with early-stage breast cancer are more likely to die from the disease than women.
Men should be included in breast cancer clinical trials, according to draft guidance issued by the FDA.
White and Black men diagnosed with early-stage breast cancer receive similar treatment, but Black men have worse outcomes.
While survival for men diagnosed with breast cancer has improved, it hasn't kept up with the improvements in survival for women with breast cancer.
The combination of either tamoxifen or an aromatase inhibitor plus a gonadotropin-releasing hormone analogue reduced levels of estradiol, a form of estrogen, more than tamoxifen alone in men diagnosed with hormone-receptor-positive breast cancer.
The expression of genes that control the number of estrogen receptors, the rate of cell division, and the ability of the cancer to invade healthy tissue was higher in breast cancers in men than in breast cancers in women.
Black men have higher rates of all types of breast cancer compared to white men in the United States.
Because not much research has been done on male breast cancer specifically, ASCO guidelines recommend managing it much the same way breast cancer is managed in women.
Experimental elacestrant offered better progression-free survival than standard hormonal therapy for post-menopausal women and men diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown during treatment with hormonal therapy and a CDK4/6 inhibitor.
While there have been no clinical trials specifically focused on male breast cancer in the United States, treatment of this disease has evolved over the years and researchers now know factors linked to better survival.
A study found that men have lower overall survival compared to women after a breast cancer diagnosis. The characteristics of the breast cancers and undertreatment of male breast cancer seem to account for much of the difference in survival.
Researchers combined the risk of common genetic variants associated with breast and prostate cancer to better estimate breast and prostate cancer risk in men with BRCA1/2 mutations.
Men diagnosed with hormone-receptor-positive breast cancer treated with tamoxifen had more than twice the risk of developing a blood clot compared to men with a similar diagnosis who were not treated with tamoxifen.
One of the largest studies of its kind has found that men with BRCA mutations developed 8 times as many cancers as would have been in expected in the general population.
The characteristics of male breast cancer associated with outcomes are different than the characteristics of female breast cancer that are associated with outcomes.